Global Kidney Cancer Drugs Industrial and Market studies 2015-2019
"Global
Kidney Cancer Drugs Market 2015-2019"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
About
Kidney Cancer
Kidney
cancer also known as renal cancer affects the kidney cells. RCC is
the most common form of kidney cancer in adults and Wilms' tumor in
children. The exact cause of the disease is not yet known. The
symptoms of renal cancer are often confused with other kidney
disorders. This usually results in late stage detection of the
disease, which leads to less chances of patient survival. In the
majority of cases, it is diagnosed accidentally, when the patient
undergoes checkups for other disorders.
Kidney
cancer can be triggered by a number of factors including both
lifestyle-related changes and genetic changes. The surgical removal
of affected cancerous cells from the kidney provides a complete cure
of the disease. A number of drugs are also available, which also help
in the treatment of the disease when it is diagnosed at earlier
stages.
Technavio's
analysts forecast the global kidney cancer drugs market to grow at a
CAGR of 7.36% over the period 2014-2019.
Covered
in this Report
The
report covers the present scenario and the growth prospects of the
global kidney cancer drugs market for 2015-2019. To calculate the
market size, the report considers the revenue generated from the
sales of various approved therapies and off-label drugs used for the
treatment of kidney cancer.
The
three regions covered in the report are as follows:
Americas:
US, Canada, Mexico, and Brazil
EMEA:
UK, Germany, Italy, France, and Spain and Middle Eastern and African
countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi
Arabia, Qatar, and UAE
APAC:
Japan, China, Australia, Singapore, South Korea, and India.
Technavio's
report, Global Kidney Cancer Drugs Market 2015-2019, has been
prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its
growth prospects in the coming years. The report also includes a
discussion of the key vendors operating in this market.
Key
Regions
Americas
APAC
EMEA
Key
Vendors
Bayer
F.
Hoffmann-La Roche
GlaxoSmithKline
Novartis
Pfizer
Other
Prominent Vendors
Abbott
Laboratories
Active
Biotech
Amgen
Argos
Therapeutics
ArQule
AVEO
Pharmaceuticals
Bionomics
Bristol-Myers
Squibb
Cerulean
Pharma
Exelixis
Genentech
immatics
biotechnologies
Immunicum
Ono
Pharmaceutical
Onyx
Therapeutics
Oxford
BioMedica
Prometheus
Laboratories
Seattle
Genetics
Taiwan
Liposome
TRACON
Pharmaceuticals
Wilex
Market
Driver
Increase
in Patient Population
For
a full, detailed list, view our report
Market
Challenge
High
Cost of Drugs
For
a full, detailed list, view our report
Market
Trend
Strategic
Alliances
For
a full, detailed list, view our report
Key
Questions Answered in this Report
What
will the market size be in 2019 and what will the growth rate be?
What
are the key market trends?
What
is driving this market?
What
are the challenges to market growth?
Who
are the key vendors in this market space?
What
are the market opportunities and threats faced by the key vendors?
What
are the strengths and weaknesses of the key vendors?
Comments
Post a Comment